Search results
Merck stock target raised on strong Q1 results By Investing.com
Investing.com· 7 days agoOn Friday, Wells Fargo adjusted its outlook on shares of pharmaceutical giant Merck & Co., Inc....
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga via AOL· 16 hours agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
Is Merck Stock Fully Valued At $130?
Forbes· 2 days agoMerck (NYSE: MRK) recently reported its Q1 results, with revenues and earnings exceeding our estimates. The growth was primarily driven by higher sales...
Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $143.00
ETF DAILY NEWS· 4 days agoMerck & Co., Inc. (NYSE:MRK – Free Report) had its target price boosted by Truist Financial from $142.00 to $143.00 in a research report released on Friday ...
Cerevance receives milestone payment under Alzheimer's collaboration with Merck
Seeking Alpha· 18 hours agoPrivately held Cerevance receives milestone payment from Merck for Alzheimer's research...
Merck's KEYTRUDA shows survival benefit in gastric cancer trial By Investing.com
Investing.com· 2 days agoMerck & Co., Inc., a leading pharmaceutical company, announced positive results from the Phase 3...
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 days agoMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats...
Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
Motley Fool via Yahoo Finance· 1 day agoThe Motley Fool has positions in and recommends Bristol Myers Squibb, Merck, and Pfizer. The Motley Fool has a disclosure policy. Pfizer's Stock Is a Buy...
What’s going on with the ImmunityBio (IBRX) stock price?
Invezz· 4 days agoImmunityBio (NASDAQ: IBRX) stock price has gone parabolic as investors cheer the recent approval of...
3 Investing Pros Lay Out Their Dividend Strategies—and Stock Picks
Barrons.com· 1 day agoBut many dividend stocks have been trailing the market. The S&P...Santoro, and “the ability to...